Alexion, Zealand to Collaborate on Peptide Therapies
March 20 2019 - 7:44AM
Dow Jones News
By Chris Wack
Alexion Pharmaceuticals Inc. (ALXN) and Zealand Pharma A/S
(ZEAL) said Wednesday that they were collaborating to discover and
develop novel peptide therapies for complement-mediated
diseases.
The companies said in a release that the agreement provides
Alexion with exclusive worldwide licenses, as well as development
and commercial rights, for up to four targets within the complement
pathway.
Under the terms of the agreement, Alexion and Zealand will enter
into an exclusive collaboration for the discovery and development
of subcutaneously delivered peptide therapies directed to up to
four complement pathway targets.
Zealand will lead the joint discovery and research efforts
through the preclinical stage, and Alexion will lead development
efforts beginning with IND filing and Phase 1 studies.
The agreement provides Alexion with exclusive worldwide licenses
and commercial rights to the peptide therapies developed in the
collaboration. Zealand will receive an immediate upfront payment of
$25 million for the first target, with Alexion making a concurrent
$15 million equity investment in Zealand Pharma at a premium to the
market price as of the collaboration effective date.
For the lead target, the agreement provides the potential for
development-related milestones of up to $115 million, as well as up
to $495 million in sales-related milestones and the potential for
high single- to low double-digit royalty payments. Each of the
three subsequent targets can be selected for an option fee of $15
million and has the potential for additional development milestones
and sales milestones and royalty payments at a reduced price to the
lead target.
Shares of Zealand were halted at $15.65 premarket.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 20, 2019 07:29 ET (11:29 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Apr 2023 to Apr 2024